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Editorial
The Importance of an Accurate Cost-Effectiveness 
Analysis for the Introduction of New Technologies in 
the Brazilian Public Health System
Raul I. Rossi Filho
M uch has changed in recent years regarding the availability of new devices for use in Interven-tional Cardiology in Brazil. 
In the 1990s, it was common to joke with our 
American colleagues that, despite the enormous eco-
nomic potential of that country, and contrary to what 
happened in Brazil, interventionists had to wait years 
to use – and gain experience with – extremely useful 
devices for the treatment of children with congenital 
heart disease.
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That has dramatically changed. With the greater 
autonomy and control of National Health Surveillance 
Agency (Agência Nacional de Vigilância Sanitária – AN-
VISA) for approving and regulating the use in humans 
of new devices not manufactured in Brazil,1,2 the gap 
between the development of increasingly better materi-
als and their clinical employment has greatly increased. 
Currently, it is no longer enough to demonstrate proof 
of efficacy and safety, or consequently obtain the re-
spected seals of approval, such as CE Mark, to allow 
access to these new materials. 
The delay in release has been of such magnitude 
that some devices, such as the Melody® valve for the 
pulmonary position, with over 14 years of continuous 
use in Europe and already approved by the Food and 
Drug Administration for use in the United States,3 has 
only recently had its use approved in Brazil. 
Readers should not think that my position is 
contrary to the regulation of new devices by ANVISA. 
Certainly not! The control of medical device is extremely 
important for the population’s health, as well as the 
financial health of the health system, and as such it 
should be treated. The thoroughness of state agency in 
controlling these matters must be supported by all of 
us. This is the only way that we can treat our patients 
with devices that that have been shown to be safe and 
efficient in the long term.
However, the bureaucratic obstacles and the small 
number of technical experts to perform this vital activity 
lead to a long wait of several years until we can treat 
our patients with the best that modern technology can 
offer in terms of health care. 
This is the current scenario for patients who can 
use the supplementary health care network, which, 
sooner or later, will have access to new technologies 
for repairing congenital heart defects. 
But what about patients who do not have access 
to the supplementary health care network and are part 
of the 70% of the population that depends on Brazil-
ian Unified Health System (Sistema Único de Saúde 
– SUS)? These are patients who we also want to treat, 
i.e. patients for whom we can make a difference when 
using percutaneous techniques with minimal clinical and 
social impact. Thus, it should be possible to reduce the 
extended stay in the increasingly scarce hospital beds, 
reducing recovery time and possibly the financial and 
occupational impact on parents who, rightly so, should 
stay with their children during the recovery period.4
Should this multitude of children wait even longer 
to have access to materials used since long in other 
countries and already available in Brazil for those who 
have access to supplementary/private health care? More-
over, should we mention the risk that other materials, 
more advanced and better, will be developed – would 
it be theory that “we should let the technology get 
older, to make it cheaper?”
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I cannot believe this is the current position be-
cause, recently, National Commission on Technology 
Incorporation (Comissão Nacional de Incorporação 
de Tecnologias – CONITEC) was restructured and has 
apparently assessed these themes with great care and 
impartiality. 
I believe that the demands of pediatric cardiolo-
gists in Brazil, responsible for the treatment of these 
children, should be evaluated with care and respect. 
For this purpose, we must do our part, which is to 
provide Brazilian Ministry of Health, responsible for the 
assessment and possible introduction of new technolo-
gies, with scientific support for proper decision-making. 
This assessment should be based on the actual needs 
of our patients, which we, as cardiologists know well, 
and also on the careful analysis of the impact of these 
new technologies on Brazil budget. The patients’ needs 
and our capacity to treat them are known by everyone 
interested in the topic and are published in national 
and international literature, either in original publica-
tions or in dissertations or doctoral theses.
However, there are very few studies on the cost-
effectiveness of using (not so) new technologies. The 
article by Costa et al.,5 published in this issue, is an 
example of how to seriously evaluate this theme. This 
group, in addition to their many contributions to in-
terventional cardiology in Brazil, has also focused on 
cost analysis procedures. 
Although most of the paying agencies of medical 
services see cost-effectiveness from the perspective of 
the cost, and not the benefit for patients, the analysis 
of incremental cost-effectiveness of treatment of patent 
ductus arteriosus performed by Costa et al.5 allows for 
the projection of the long-term impact of the use of this 
new technology. And the result, after a stringent review 
of the literature, demonstrated that a small reduction 
in the current cost of the material used will allow for 
the use of this technique in patients who need it most. 
I hope this publication will be followed by many 
others, creating a scientifically sound theoretical basis, 
on which Brazilian Ministry of Health, urged by our 
society and with the support of the civil society, can 
rely on to make decisions about the incorporation of 
new devices that bring real benefits to our population.
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